2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173311
    Cbl-b-IN-28
    Cbl-b-IN-28 (Compound B2) is an orally active Cbl-b inhibitor. Cbl-b-IN-28 promotes the secretion of cytokines such as IL-2 and enhances the function of immune cells by regulating the phosphorylation levels of key proteins in the T-cell receptor signaling pathway. Cbl-b-IN-28 can be used in research in the field of cancer immunology.
    Cbl-b-IN-28
  • HY-173316
    STING-IN-12
    STING-IN-12 (compound Y2) is an inhibitor of STING. STING-IN-12 inhibits IFNβ gene expression (IC50=0.75μM) induced by SR717. STING-IN-12 inhibits STING pathway activation induced by the STING agonist SR717 in THP1 cells and MSA-2-induced STING pathway activation in vivo in mice.
    STING-IN-12
  • HY-173317
    STING-IN-13
    STING-IN-13 is a selective STING inhibitor. STING-IN-13 can effectively inhibit downstream signaling of the STING pathway and inhibit STING-mediated inflammation. STING-IN-13 has low toxicity and can be used to study STING-related inflammatory and autoimmune diseases.
    STING-IN-13
  • HY-173321
    PAD4-IN-5 3071873-52-1
    PAD4-IN-5 (Example 18) is a PAD4 inhibitor with IC50s of ≤10 nM and 101-500 nM for human PAD4 (hPAD4) under 50 µM Ca2+ and 1 mM Ca2+ conditions, respectively. PAD4-IN-5 can be used for the study of autoimmune disease, such as rheumatoid arthritis (RA).
    PAD4-IN-5
  • HY-173326
    STING-IN-14 3070953-78-2
    STING-IN-14 is an inhibitor of STING (IC50: 0.6 nM). STING-IN-14 inhibits the activation of the IRF pathway in THP1-DualTM cells. STING-IN-14 can be used in autoimmune diseases research.
    STING-IN-14
  • HY-173340
    LRH-1 agonist-1
    LRH-1 agonist-1 (compound 74) is an agonist of LRH-1 with IC50 value of 47 μM.
    LRH-1 agonist-1
  • HY-173357
    TYD-68
    TYD-68 is a highly efficient and selective CRBN-recruited TYK2 PROTAC degrader with a DC50 value of 0.42 nM. TYD-68 significantly inhibits IL-12 and IFN-α-induced STAT4 and STAT1 phosphorylation, thereby blocking TYK2-dependent signaling pathways. TYD-68 can be used in the study of psoriasis. (Pink: Target protein ligand (HY-173359); Black: Linker (HY-W007732B); Blue: E3 ligase ligand (HY-14658); E3 ligase ligand + Linker (HY-173358)).
    TYD-68
  • HY-173359
    TYK2 ligand 2 2924460-80-8
    TYK2 ligand 2 is a TYK2 ligand for TYD-68 (HY-173357). TYD-68 is a highly efficient and selective CRBN-recruited TYK2 PROTAC degrader with a DC50 value of 0.42 nM. TYD-68 can be used in the study of psoriasis.
    TYK2 ligand 2
  • HY-173383
    DOPE-DOTA sodium
    DOPE-DOTA sodium is a chelated lipid that serves as a key contrast agent in magnetic resonance imaging (MRI). DOPE-DOTA sodium can be used for cancer, blood-brain barrier disruption, abnormalities such as aneurysms or plaque buildup, inflammation in arthritis, and liver function and lesions study
    DOPE-DOTA sodium
  • HY-173384
    DSPE-DOTA sodium
    DSPE-DOTA sodium (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- tetraazacyclododecane-N-tetraacetic acid, sodium salt) is a chelating lipid used as a key contrast agent in magnetic resonance imaging (MRI). DSPE-DOTA sodium can be used for imaging detection of tumors, neurological and inflammatory diseases.
    DSPE-DOTA sodium
  • HY-173399
    hSTING activator-1
    hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.
    hSTING activator-1
  • HY-173404
    VB-85247
    VB-85247 is a STING agonist. VB-85247 induces upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as maturation and activation of dendritic cells by activating the STING pathway. VB-85247 can achieve regression of intrabladder tumors and can be used in bladder cancer research.
    VB-85247
  • HY-173407
    P2Y14R antagonist 4 3081687-67-1
    P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release.
    P2Y14R antagonist 4
  • HY-173409
    AR antagonist 11 3005979-40-5
    AR antagonist 11 (Compound c2) is a selective AR antagonist with an IC50 of 0.019 μM. AR antagonist 11 is also effective against ARF877L/T878A mutant (IC50: 1.03 μM). AR antagonist 11 inhibits LNCaP cell proliferation and reduces PSA protein expression (IC50: 0.54 μM). AR antagonist 11 can be used for research of prostate cancer (PCa).
    AR antagonist 11
  • HY-173410
    iNOs-IN-6
    iNOs-IN-6 is an anti-inflammatory agent. iNOs-IN-6 inhibits NF-κB, iNOS, and MAPK expression(IC50: 0.2-0.62 μM). iNOs-IN-6 reduces IL-6, TNF-α, and IL-1β pro-inflammatory mediators levels (IC50: 0.4-0.69 μM).
    iNOs-IN-6
  • HY-173411
    DNJ-20 3081926-49-7
    DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research.
    DNJ-20
  • HY-173414
    PROTAC STING degrader-3
    PROTAC STING degrader-3 (Compound ST9) is a STING PROTAC degrader (DC50: 0.62 μM). PROTAC STING degrader-3 induces STING degradation via the ubiquitin-proteasome pathway. PROTAC STING degrader-3 exerts anti-inflammatory effects by inhibiting STING/TBK1/NF-κB signaling. PROTAC STING degrader-3 has renal protective effects and can be used in the study of acute kidney injury (AKI) (Pink: STING ligand (HY-47709); Blue: E3 ligase CRBN ligand (HY-41547); Black: linker).
    PROTAC STING degrader-3
  • HY-173416
    Anti-inflammatory agent 100
    Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory agent. Anti-inflammatory agent 100 inhibits MAPK and NF-κB signaling, and also inhibits NF-κB pathway by suppressing the phosphorylation of IκB-α and blocking nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 inhibits NO production (IC50: 0.5 μM) and TNF-α, IL-6, IL-1β secretion.
    Anti-inflammatory agent 100
  • HY-173443
    SP-C01 2982533-42-4
    SP-C01 is an orally active soluble epoxide hydrolase (sEH) inhibitor and partial PPARγ agonist. SP-C01 can inhibit Ser273 phosphorylation.
    SP-C01
  • HY-173454
    RIPK2/3-IN-2
    RIPK2/3-IN-2 (29) is a dual RIPK2 and RIPK3 inhibitor, with IC50 values of 12 nM and 18 nM, respectively. RIPK2/3-IN-2 (29) induces necroptosis, with an EC50 of 0.16 μM.
    RIPK2/3-IN-2
Cat. No. Product Name / Synonyms Application Reactivity